Viral Vectors and Plasmid DNA Manufacturing Market 2019 with Key Players Kaneka Eurogentec S.A., FinVector, Brammer Bio, Cell and Gene Therapy Catapult, Transgene

The global viral vector and plasmid DNA manufacturing market size was valued at US$ 290.0 million in 2017, and is expected to exhibit a CAGR of 22.5% over the forecast period (2018 – 2026).

Viral vector and plasmid DNA manufacturing is used in application of gene therapy to diagnose and treat diseases in patients. High prevalence of cancer is expected to propel demand for gene therapy, which in turn is expected to drive the market growth. According to World Health Organization (WHO), 2012, cancer is the second leading cause of morbidity and mortality worldwide, with around 14 million new cases registered in 2012, and was responsible for 8.8 million deaths worldwide in 2015. Moreover, WHO stated that, the number of new cases of cancer is expected to rise by around 70% by the end of 2030.

Similarly, according to the International Quarterly Journal of Research in Ayurveda, published in 2010, estimated around 20 – 30% of all infant deaths are due to genetic disorders, and around 11.1% of pediatric hospital admissions are for children with inherited disorders.

Furthermore, rising awareness regarding gene therapy is propelling growth of the viral vector and plasmid DNA manufacturing market over the forecast period. For instance, in November 2018, the National Institutes of Health (NIH) launched a new initiative to accelerate adoption of gene therapy to cure around 20 million patients diagnosed with sickle cell disease.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/962

However, complications such as risk of mutagenesis, safety and efficacy issues, and stringent regulatory framework are expected to limit the adoption of gene therapy, thereby hindering the market growth

North America holds a dominant position in the global viral vector and plasmid DNA manufacturing market, owing to high prevalence of viral infection in the region. According to the National Center for Biotechnology Information (NCBI) report, published in December 2017, around 98 cases diagnosed with Powassan Virus were reported from 1999 to 2016, with an increase of 671% cases from 1999 to 2016.

Moreover, increasing research and development activities in the field of viral vector and plasmid DNA manufacturing is expected to enhance its demand in the near future. For instance, in April 2017, Transgene announced plans for a new clinical research collaboration of investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) with standard chemotherapy (CT) as a first-line treatment for advanced non-squamous, non-small cell lung cancer (NSCLC) in patients, which is under Phase 2 clinical trial.

Key Players

Major players operating in the global viral vector and plasmid DNA manufacturing market include, Kaneka Eurogentec S.A., FinVector, Brammer Bio, Cell and Gene Therapy Catapult, Transgene SA, FUJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, Cobra Biologics, UniQure, MassBiologics, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Ltd., and Thermo Fisher Scientific, Inc.

Get Discount On This Report:
https://www.coherentmarketinsights.com/insight/request-discount/962

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.